NEW YORK (AP) ¿ Life sciences companies that depend on research dollars from big pharma could see a downturn in contracts if pharmaceutical companies continue buying each other and cutting costs. On Monday, Whitehouse Station, N.J.-based Merck & Co. said it is buying Kenilworth, N.J.-based Schering-Plough Corp. for $41.1 billion in the latest industry consolidation. Earlier this year, New York-based Pfizer Inc. said it would buy Madison, N.J.-based Wyeth for $68 billion. In each case, the companies making the acquisitions are looking to shore up their development pipelines while saving operating costs, which includes research and development. In a note to clients late Monday, Thomas Weisel Partners analyst Peter Lawson said the latest buyouts could pressure other companies to combine as they lose patent protection on blockbuster drugs and see generic competition cut into revenue. "We believe research and development cost cutting would serve to reduce visibility for capital spending by pharma in the short term," he said. He said Merck spent about $4.68 billion in research and development in 2008 while Schering-Plough spent about $3.52 billion. He had expected biopharma research and development growth of 4.3 percent in 2010, but that could be limited to 2.2 percent because of the Pfizer-Wyeth deal. Considering both the Pfizer-Wyeth deal and the merger of Merck and Schering-Plough, growth could be less than 1 percent.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Beyond Meat Slides After Andrew Left's Citron Slams Stock in Tweet
Newly public meat-alternative company sees shares lower on short-seller's critique.
Baidu, Alibaba and Tencent All Reported This Week: A Chinese Tech Scorecard
China's tech giants gave a look into how they're faring amid trade worries and other macro factors.
Stock Exchanges in Need of Reform. Is the Long-Term Stock Exchange the Answer?
Tech companies could find a friendly home in the Long-Term Stock Exchange, but whether everyday investors will embrace remains an open question.
Kohl's and 2 Other Retail Earnings That Every Investor Should Watch Next Week
Feeling overwhelmed as the markets gear up for retail earnings palooza? Action Alerts PLUS senior analyst Jeff Marks is watching three key retail earnings.